VI. Multilateral Institutions

  1. The World Health Organization
    • Would further centralization of medicines regulatory activities at the WHO contribute to medicines development efficiencies and help reduce medicines costs?
    • Does centralization raise risks of industry capture?
    • What should be the follow up to the Commission on Intellectual Property Rights, Innovation and Public Health report?

  2. World Trade Organization
    • Can the TRIPS Council better account for the differential public welfare consequences of IP rights?
    • Should the WTO do more to address the proliferation of TRIPS-plus FTAs in light of the Doha Declaration on the TRIPS Agreement and Public Health?

  3. World Intellectual Property Organizations
    • Might problems with patent quality in the pharmaceutical sector be addressed at the multilateral level?
    • Might a patent opposition system at the multilateral level be envisaged?

  4. United Nations Human Rights
    • How can multilateral human rights conventions and rules inform the discussion of pharmaceutical regulation and issues concerning patient access?

  5. United Nations Conference on Trade and Development
    • How can UNCTAD programs on transfer of technology and local production of pharmaceuticals improve research and development, local industrial development and security, and patient access?
    • How can UNCTAD best cooperate with other multilateral institutions?



The Panel | Agenda